
Veteran Wall Street analyst with 20+ years in equity research, co-founder of a 700K-subscriber financial publisher, former Morgan Stanley consultant, and regular contributor to FOX Business and CNBC.
No link addedGain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
